Life Sciences

Life science in the era of pandemics: 2 years on

06/2022
holding lame and lamelle in front of a microscope

Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.

When the pandemic struck in 2020, Chubb and legal partner Kennedys produced a series of reports  exploring the impact it was having on the life science industry through the lenses of clinical trials, medical devices, telehealth, genomics and the supply chain.

Looking back at the past two years, the industry has, by and large, proved successful at managing the most significant risks faced. It has also demonstrated its capabilities during an extraordinary time; producing vaccines at record speed and rapidly delivering solutions – from telehealth to medical devices and genomic surveillance – that have helped us through this difficult period. Now the life science sector is building on that foundation to improve healthcare and preparedness for future pandemics, while continuing to battle COVID-19.

Read “The new normal in life science” report for insights on how those changes played out in the medium term. Which innovations have become part of the new normal and where did things go wrong? From the new strength and capacity that has been built in telehealth and clinical trials, to the lessons that have been learnt for future pandemics on medical devices and supply chains.

Key takeaways

  • Supply chain visibility is now a key focus at c-level, enabled by technology.
  • Decentralised trials could be here to stay but decentralising patient recruitment is still a way off.
  • Genomic research still has a lot more to offer during this pandemic.
  • Research needs to be more inclusive to ensure the benefits of genomics are enjoyed by all.
  • Fostering innovation in the context of remote working is the next challenge.
Download

The new normal in life science

Read more reports in the ‘Life Science in the era of pandemics’ series:

Insights and Expertise

We keep you informed — and your business protected — with these helpful articles.
a doctor using tablet
The great telehealth experiment
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
medical devices
Making medical devices during a pandemic
How has the coronavirus pandemic affected the risk profile of medical device manufacturing?
medical equipment
3 big questions with life science expert Travis McIntosh
What do the new COVID-19 vaccines mean to insurers and the Life Science industry at large? How has COVID-19 affected Life Science companies?
abstract virus
Emerging risks in COVID-19 clinical trials
As the scientific community races to respond to COVID-19, best practice is slipping in clinical trials. What trade-offs are being made and who is liable?
bright dna spiral
Fighting COVID-19 with genomics
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare
lessons from the supply chain
Lessons from the supply chain
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds. But, behind the headlines, how is the pandemic affecting attitudes to risk?

Have a question or need more information?

Contact us to find out how we can help you get covered against potential risks.